Cantor Fitzgerald Maintains Neutral on Rigel Pharmaceuticals, Raises Price Target to $47
Benzinga Newsdesk 7 hours ago
Analyst RatingsNewsPrice Target
Cantor Fitzgerald analyst Kristen Kluska maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Neutral and raises the price target from $43 to $47.
Cantor Fitzgerald analyst Kristen Kluska maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Neutral and raises the price target from $43 to $47.